Board of Directors

Rich Whitely, MD

Virologist

  • Gilead's Board of Director

  • Distinguished Professor Loeb Scholar Chair in Pediatrics, and Professor of Microbiology, Medicine and Neurosurgery, UAB

  • Co-Founder & Co-Director, 

  • Alabama Drug Discovery Alliance

  • 380 Publications

  • Obama H1N1 Task Force

  • Remdesivir was Originally Developed by Dr Whitley’s team at UAB

Abel DeLaRosa, PhD

Virologist

  • CEO, Director, co-founder of Antios Therapeutics

  • Chief Scientific Officer of Drug Innovation Ventures at Emory

  • Led acquisition of Pharmasset by Gilead Sciences (NASDAQ: GILD) for $11.5 billion in 2012

  • Led Drug Development Programs for the Treatment of HIV, Hepatitis B and C, including Sofosbuvir 

John Thomas, CPA

CFO/Director/Audit Chair

  • CorMatrix Cardiovascular DemeRx, Inc.

  • MiMedx Group, Inc. 

  • DARA BioSciences

  • GMP Companies 

  • MRI Interventions

  • EnterMed, Inc. 

  • Medicis Pharm Corp. 

  • CytRx Corp

Rick Keefer

Director

  • 30-year Pharma industry veteran with broad-based experience in leading commercial operations.

  • Seven-time winner of Pharma Voice’s top 100 leaders in healthcare

  • Executive roles at Pharmacia, Pfizer, Wyeth, Biovail and Publicis Health

Skip Pridgen, MD Founder

Director

  • Company Founder

  • Board- certified surgeon practicing with Tuscaloosa Surgical Associates, P.C.

  • Spent nearly 20 years searching for effective treatments in IBS, FM, and CFS/ME

  • Served as a physician and surgeon in the United States Navy

Greg Duncan

Director

  • FPO

Rick Burch

Director

  • FPO

© 2020 Virios Therapeutics.